The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), shares his thoughts on the ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses findings from the report and the ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...

Andrew Mackinnon, Executive GM, Medable, discusses how AI-driven innovations are streamlining clinical trials through ...

Leveraging artificial intelligence-powered stochastic methods for clinical data review represents a significant leap beyond ...

Data in and of itself can be interesting, but the true value of data lies in how you use it and the insights that come from ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses industry’s next steps in being ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...